Rilpivirine's trial programme did two things: it established the drug as better tolerated than efavirenz, and it produced the finding that limits who can start on it.
What did ECHO and THRIVE test?
Rilpivirine against efavirenz in people starting treatment, across two parallel trials. Overall suppression rates were comparable, and the pattern underneath differed considerably between the two drugs.
What was the difference?
Efavirenz participants discontinued more often for side effects. Rilpivirine participants had more virological failure. The two effects roughly cancelled out in the headline figure while pointing to very different problems.
Where did the failures concentrate?
Among participants starting with a viral load above 100,000 copies, where rilpivirine performed noticeably worse. Below that threshold the two drugs were comparable, which is the basis for the restriction in its licensing.
What about CD4 count?
Lower CD4 counts at baseline were also associated with poorer outcomes, which is why guidance considers both measures rather than viral load alone.
What did the resistance analysis show?
Participants who failed on rilpivirine frequently developed non-nucleoside resistance and, in many cases, resistance to the nucleoside backbone as well. That combination limits what remains usable afterwards, which is a meaningful consideration.
What about tolerability?
Consistently better than efavirenz. Rash, dizziness, abnormal dreams and neuropsychiatric events were all substantially less frequent, and lipid effects were more favourable.
What did the switch studies show?
People already suppressed on other regimens maintained suppression after switching to rilpivirine-containing combinations, with improvements in lipids for those coming off boosted regimens. This is where the drug fits best.
What established the two-drug combination with dolutegravir?
The SWORD studies, which showed that suppressed people could switch to dolutegravir with rilpivirine and remain suppressed. That was among the first demonstrations that two drugs could maintain treatment.
What did ATLAS and FLAIR establish?
That long-acting injectable rilpivirine with cabotegravir, given monthly, maintained suppression as well as daily oral therapy in people already suppressed. ATLAS-2M later showed two-monthly dosing worked equally well.
What did participants say?
Most preferred injections to daily tablets despite injection site reactions being common. That preference has been consistent across studies and reflects how much the daily reminder weighs on some people.
What is known about the food effect?
Pharmacokinetic studies showed absorption falling substantially when taken fasted, and a protein drink or light snack proving insufficient. A normal meal of around five hundred calories is what the dosing assumes.
What about heart rhythm?
At doses well above the therapeutic one, rilpivirine prolongs the QT interval. At the licensed dose this is not generally a concern, and caution applies alongside other drugs with the same effect.
What about pregnancy?
Studies have shown levels falling during pregnancy, which risks inadequate concentrations. That is why it is not generally a preferred option and may need monitoring or changing.
What is still being studied?
Mainly its role in long-acting regimens and in further simplification. Its oral properties are well established.
Where can you read the evidence yourself?
NAM aidsmap summarises HIV research reliably, and the British HIV Association publishes the guidelines UK clinicians follow. Both are freely available and considerably more useful than a general search.